Comera Life Sciences Holdings, Inc.
CMRA
$0.0001
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -56.74% | -19.80% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -56.74% | -19.80% | |||
| Cost of Revenue | -25.00% | -51.93% | |||
| Gross Profit | -63.59% | -6.30% | |||
| SG&A Expenses | 21.49% | -36.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 27.74% | -37.95% | |||
| Operating Income | -45.73% | 40.80% | |||
| Income Before Tax | -52.57% | 43.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -52.57% | 43.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -52.57% | 43.11% | |||
| EBIT | -45.73% | 40.80% | |||
| EBITDA | -46.63% | 41.13% | |||
| EPS Basic | -23.91% | 42.03% | |||
| Normalized Basic EPS | -26.25% | 43.44% | |||
| EPS Diluted | -23.91% | 42.03% | |||
| Normalized Diluted EPS | -26.25% | 43.44% | |||
| Average Basic Shares Outstanding | 20.67% | 0.64% | |||
| Average Diluted Shares Outstanding | 20.67% | 0.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||